Abstract:The C‐X‐C motif chemokine ligand 8 (CXCL8)‐C‐X‐C chemokine receptor (CXCR)1/2 signalling axis is among numerous mechanisms which stimulate the immune system to defend against tumour growth and influence the tumour microenvironment to promote tumour growth. This pathway plays an important role in the development of a number of cancers including breast cancer (BC). The aim of the present study was to analyse the levels of the chemokine CXCL8 and its receptors, CXCR1 and CXCR2, in the serum of female patients with invasive BC and to assess the expression of these parameters at the mRNA level, considering molecular subtypes and degrees of cancer malignancy. The study group consisted of 62 patients with histopathologically confirmed invasive BC. The control group consisted of 18 patients with histopathologically confirmed fibroadenoma, a benign breast tumour. The levels of CXCL8, CXCR1 and CXCR2 were determined by sandwich ELISA using the CLOUD‐CLONE ELISA kit. CXCL8, CXCR1 and CXCR2 transcript levels were analysed using reverse transcription‐quantitative PCR. Results showed that serum CXCL8 levels in female patients with invasive BC were significantly higher compared with those in the control group (P<0.05). In addition, significantly elevated CXCR1 levels were observed in luminal B human epidermal growth factor receptor 2+ carcinoma compared with those in the control group. Analysis of CXCL8 in the serum of female patients with BC showed a statistically significant difference between clinical stage G1 and G2 (P<0.05), G2 and G3 (P<0.01), and G1 and G3 (P<0.0001). On the other hand, the analysis of CXCR1 and CXCR2 levels in the serum of the patients revealed a statistically significant difference between G2 and G3 (P<0.05). The current study showed that abnormalities in the immune response involving the CXCL8‐CXCR1/2 signalling axis in patients with invasive BC are involved in the development of these tumours. Moreover, the demonstrated severity of changes occurring at protein level may suggest the potential usefulness of their determination as potential diagnostic markers in the clinic.

Involvement in Tumorigenesis and Clinical Significance of CXCL1 in Reproductive Cancers: Breast Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer and Prostate Cancer

The Clinical Significance and Involvement in Molecular Cancer Processes of Chemokine CXCL1 in Selected Tumors

The Clinical Significance and Role of CXCL1 Chemokine in Gastrointestinal Cancers

CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications

Clinical Significance of CXCL13/CXCR5 Axis in Human Cancers

CXCR2 Receptor: Regulation of Expression, Signal Transduction, and Involvement in Cancer

Fractalkine/CX3CL1 in Neoplastic Processes

A S100A14-CCL2/CXCL5 signaling axis drives breast cancer metastasis

Clinical significance of the CXCL8/CXCR1/R2 signalling axis in patients with invasive breast cancer

Revisiting the CXCL13/CXCR5 Axis in the Tumor Microenvironment in the Era of Single-cell Omics: Implications for Immunotherapy

The Importance of CXCL1 in the Physiological State and in Noncancer Diseases of the Oral Cavity and Abdominal Organs

The Role and Clinical Significance of the CXCL17-CXCR8 (GPR35) Axis in Breast Cancer

The Potential Importance of CXCL1 in the Physiological State and in Noncancer Diseases of the Cardiovascular System, Respiratory System and Skin

The CXCL8-CXCR1/2 pathways in cancer

The Role of CXCL11 and its Receptors in Cancer: Prospective but Challenging Clinical Targets

The Role of CXCR3 and Its Ligands in Cancer

Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival.

CXCL3: A key player in tumor microenvironment and inflammatory diseases

CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target

The Significance of Selected C-C Motif Chemokine Ligands in Colorectal Cancer Patients

Chemokine (C-X-C Motif) Ligand 1 is Associated with Tumor Progression and Poor Prognosis in Patients with Colorectal Cancer